In Q3 2016, the company reported $633 million in net income attributable to McKesson. This is a 0.16 decline from the $634 million reported in 2015.
The company also reported its revenue for Q3 was $50.1 billion, a 5 percent increase from the $47.9 billion the company reported a year prior.
“I am pleased with our strong cash flow generation and our ability to deploy capital in meaningful and productive ways, particularly strategic acquisitions and share repurchases,” said McKesson Chairman and CEO John Hammergren. “Although we were unfavorably impacted in the third quarter by weaker branded pharmaceutical pricing than anticipated, we are updating our fiscal 2017 outlook to reflect McKesson’s lower full-year effective tax rate.”
More articles on health IT:
Viewpoint: Longer lifespans aren’t to blame for rising healthcare costs
Lundbeck, IBM Watson Health partner to develop psychiatric drugs
ONC: Immunization, laboratory results top list of most reported public health data
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
